DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • India
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
RUBICON logo

Rubicon Research Limited Stock Price

NSEI:RUBICON Community·₹303.8b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 8 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

RUBICON Share Price Performance

₹1,835.40
1207.20 (192.17%)
​
₹1,897.50
Fair Value
₹1,835.40
1207.20 (192.17%)
3.3% undervalued intrinsic discount
₹1,897.50
Fair Value
Price ₹1,835.40
AnalystConsensusTarget ₹1,897.50
Mon, 24 Aug 26
Fair Value₹1,897.50
Share Pricen/a

RUBICON Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value ₹1.9k 3.3% undervalued intrinsic discount

Future Manufacturing Capacity And Specialty Focus Will Support A Fairly Valued Outlook

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
RUBICON logo
Rubicon Research
3.3% undervalued intrinsic discount

Future Manufacturing Capacity And Specialty Focus Will Support A Fairly Valued Outlook

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Published 24 Aug
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
RUBICON logo

Future Manufacturing Capacity And Specialty Focus Will Support A Fairly Valued Outlook

Fair Value: ₹1.9k 3.3% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Exceptional growth potential with outstanding track record.

0 Risks
2 Rewards
View Full Analysis

Rubicon Research Limited Key Details

₹19.4b

Revenue

₹6.4b

Cost of Revenue

₹13.0b

Gross Profit

₹10.1b

Other Expenses

₹2.9b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
17.41
67.00%
14.89%
24.1%
View Full Analysis

About RUBICON

Founded
1999
Employees
1290
CEO
Parag Sancheti
WebsiteView website
www.rubicon.co.in

Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. The company develops products in the areas of analgesics/pain management, cardiovascular system, central nervous system, hypokalemia, skeletal muscle relaxants, nicotine replacement therapy, gastrointestinal, metabolic, and immunosuppressant. Its primary proprietary technologies for drug delivery comprising RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption, as well as RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies. The company was incorporated in 1999 and is headquartered in Mumbai, India.

Recent RUBICON News & Updates

User avatar
New Narrative • Aug 24

Future Manufacturing Capacity And Specialty Focus Will Support A Fairly Valued Outlook

Catalysts About Rubicon Research Rubicon Research focuses on developing and manufacturing specialty and differentiated pharmaceutical products for global markets. What are the underlying business or industry changes driving this perspective?

Recent updates

No updates

Rubicon Research Limited Competitors

SUNPHARMA logo

Sun Pharmaceutical Industries

Symbol: NSEI:SUNPHARMA
Market cap: ₹4.4t
DIVISLAB logo

Divi's Laboratories

Symbol: NSEI:DIVISLAB
Market cap: ₹2.5t
500420 logo

Torrent Pharmaceuticals

Symbol: BSE:500420
Market cap: ₹1.9t
ZYDUSLIFE logo

Zydus Lifesciences

Symbol: NSEI:ZYDUSLIFE
Market cap: ₹1.1t
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide